192 related articles for article (PubMed ID: 15488027)
1. Bcl-2 expression inversely correlates with tumour cell differentiation in medulloblastoma.
Schüller U; Schober F; Kretzschmar HA; Herms J
Neuropathol Appl Neurobiol; 2004 Oct; 30(5):513-21. PubMed ID: 15488027
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of classical vs. desmoplastic medulloblastomas.
Pramanik P; Sharma MC; Mukhopadhyay P; Singh VP; Sarkar C
Neurol India; 2003 Mar; 51(1):27-34. PubMed ID: 12865511
[TBL] [Abstract][Full Text] [Related]
3. Medulloblastoma: histopathologic and molecular markers of anaplasia and biologic behavior.
Min HS; Lee YJ; Park K; Cho BK; Park SH
Acta Neuropathol; 2006 Jul; 112(1):13-20. PubMed ID: 16691420
[TBL] [Abstract][Full Text] [Related]
4. A clinicobiological model predicting survival in medulloblastoma.
Ray A; Ho M; Ma J; Parkes RK; Mainprize TG; Ueda S; McLaughlin J; Bouffet E; Rutka JT; Hawkins CE
Clin Cancer Res; 2004 Nov; 10(22):7613-20. PubMed ID: 15569993
[TBL] [Abstract][Full Text] [Related]
5. Effects of basic fibroblast growth factor on the differentiation, growth, and viability of a new human medulloblastoma cell line (UM-MB1).
Kenigsberg RL; Hong Y; Yao H; Lemieux N; Michaud J; Tautu C; Théorêt Y
Am J Pathol; 1997 Sep; 151(3):867-81. PubMed ID: 9284836
[TBL] [Abstract][Full Text] [Related]
6. Survivin is a negative prognostic marker in medulloblastoma.
Pizem J; Cört A; Zadravec-Zaletel L; Popovic M
Neuropathol Appl Neurobiol; 2005 Aug; 31(4):422-8. PubMed ID: 16008826
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of fibroblast growth factors (FGFs) for medulloblastoma may correlate with FGF receptor expression and tumor variant.
Duplan SM; Théorêt Y; Kenigsberg RL
Clin Cancer Res; 2002 Jan; 8(1):246-57. PubMed ID: 11801566
[TBL] [Abstract][Full Text] [Related]
8. Neurotrophin receptors and heparanase: a functional axis in human medulloblastoma invasion.
Marchetti D; Mrak RE; Paulsen DD; Sinnappah-Kang ND
J Exp Clin Cancer Res; 2007 Mar; 26(1):5-23. PubMed ID: 17550129
[TBL] [Abstract][Full Text] [Related]
9. Histopathological prognostic factors in medulloblastoma: high expression of survivin is related to unfavourable outcome.
Haberler C; Slavc I; Czech T; Gelpi E; Heinzl H; Budka H; Urban C; Scarpatetti M; Ebetsberger-Dachs G; Schindler C; Jones N; Klein-Franke A; Maier H; Jauk B; Kiefer A; Hainfellner JA
Eur J Cancer; 2006 Nov; 42(17):2996-3003. PubMed ID: 16996732
[TBL] [Abstract][Full Text] [Related]
10. Prediction of prognosis in children with medulloblastoma by using immunohistochemical analysis and tissue microarray.
Shim KW; Joo SY; Kim SH; Choi JU; Kim DS
J Neurosurg Pediatr; 2008 Mar; 1(3):196-205. PubMed ID: 18352763
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of survivin splice isoforms in medulloblastomas.
Li XN; Shu Q; Su JM; Adesina AM; Wong KK; Perlaky L; Antalffy BA; Blaney SM; Lau CC
Neuropathol Appl Neurobiol; 2007 Feb; 33(1):67-76. PubMed ID: 17239009
[TBL] [Abstract][Full Text] [Related]
12. The potential role of Bcl-2 expression, apoptosis and cell proliferation (Ki-67 expression) in cases of gastric carcinoma and correlation with classic prognostic factors and patient outcome.
Tsamandas AC; Kardamakis D; Tsiamalos P; Liava A; Tzelepi V; Vassiliou V; Petsas T; Vagenas K; Zolota V; Scopa CD
Anticancer Res; 2009 Feb; 29(2):703-9. PubMed ID: 19331225
[TBL] [Abstract][Full Text] [Related]
13. Microvessel density and vascular endothelial growth factor expression as predictors of childrens' survival from cerebellar medulloblastoma.
Tural S; Gercek A; Konya D; Ozgen S; Toplamoglu H; Ozek MM
J Clin Neurosci; 2009 Sep; 16(9):1199-202. PubMed ID: 19524442
[TBL] [Abstract][Full Text] [Related]
14. Anti-proliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells.
von Bueren AO; Shalaby T; Rajtarova J; Stearns D; Eberhart CG; Helson L; Arcaro A; Grotzer MA
BMC Cancer; 2007 Jan; 7():19. PubMed ID: 17254356
[TBL] [Abstract][Full Text] [Related]
15. Nevoid basal cell carcinoma syndrome: relation with desmoplastic medulloblastoma in infancy. A population-based study and review of the literature.
Amlashi SF; Riffaud L; Brassier G; Morandi X
Cancer; 2003 Aug; 98(3):618-24. PubMed ID: 12879481
[TBL] [Abstract][Full Text] [Related]
16. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma.
Gajjar A; Hernan R; Kocak M; Fuller C; Lee Y; McKinnon PJ; Wallace D; Lau C; Chintagumpala M; Ashley DM; Kellie SJ; Kun L; Gilbertson RJ
J Clin Oncol; 2004 Mar; 22(6):984-93. PubMed ID: 14970185
[TBL] [Abstract][Full Text] [Related]
17. A clinicopathologic and immunohistochemical analysis of 53 cases of medulloblastoma with emphasis on synaptophysin expression.
Coffin CM; Braun JT; Wick MR; Dehner LP
Mod Pathol; 1990 Mar; 3(2):164-70. PubMed ID: 2109316
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis in prostate cancer: bax correlation with stage.
Amirghofran Z; Monabati A; Gholijani N
Int J Urol; 2005 Apr; 12(4):340-5. PubMed ID: 15948719
[TBL] [Abstract][Full Text] [Related]
19. Low-level copy gain versus amplification of myc oncogenes in medulloblastoma: utility in predicting prognosis and survival. Laboratory investigation.
Takei H; Nguyen Y; Mehta V; Chintagumpala M; Dauser RC; Adesina AM
J Neurosurg Pediatr; 2009 Jan; 3(1):61-5. PubMed ID: 19119907
[TBL] [Abstract][Full Text] [Related]
20. Medulloblastoma with myogenic differentiation showing double immunopositivity for synaptophysin and myoglobin.
Kido M; Ueno M; Onodera M; Matsumoto K; Imai T; Haba R; Tamiya T; Huang CL; Sakamoto H
Pathol Int; 2009 Apr; 59(4):255-60. PubMed ID: 19351370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
